StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a report released on Wednesday morning. The firm issued a sell rating on the stock. Separately, Roth Capital reiterated a buy rating on shares of Bio-Path in a research report on Friday, March 17th. Bio-Path Price Performance Shares of NASDAQ:BPTH opened at $1.65 […]